The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] Formoterol Fumarate results in decreased expression of ACTA2 mRNA; Formoterol Fumarate results in decreased expression of ACTA2 protein
[Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB1 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB1 protein]
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Dactinomycin inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; Formoterol Fumarate binds to and results in increased activity of ADRB2 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA] Formoterol Fumarate results in increased phosphorylation of ADRB2 protein Formoterol Fumarate results in increased activity of ADRB2 protein
[Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Formoterol Fumarate binds to and results in increased activity of ADRB3 protein; Formoterol Fumarate inhibits the reaction [cyanopindolol binds to ADRB3 protein]
Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]
[Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL13 protein]
[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate]
desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]]; desisobutyrylciclesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein]; Formoterol Fumarate promotes the reaction [desisobutyrylciclesonide inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]] Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]
Formoterol Fumarate affects the expression of IL6 mRNA; Formoterol Fumarate affects the expression of IL6 protein Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Formoterol Fumarate results in increased expression of IL6 mRNA
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK1 protein
[Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Formoterol Fumarate results in increased phosphorylation of and results in increased activity of MAPK3 protein
[Formoterol Fumarate co-treated with desisobutyrylciclesonide] inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein]; Formoterol Fumarate inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased phosphorylation of MAPK8 protein]
Budesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]; Formoterol Fumarate promotes the reaction [Budesonide inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Ipratropium promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium results in increased activity of MMP9 protein]]
Budesonide inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; Fluticasone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [beclomethasone 17-monopropionate results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Budesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [desisobutyrylciclesonide results in decreased transport of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Fluticasone results in decreased transport of Formoterol Fumarate]
Formoterol Fumarate affects the expression of TNF mRNA; Formoterol Fumarate affects the expression of TNF protein [TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate] Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Formoterol Fumarate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]